MedTrace Logo

Narval CC Mandibular Repositioning Device in the Second-line Treatment of Severe Obstructive Sleep Apnea Hypopnea (OSAH)

NCT01326143 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 360

Last updated 2020-04-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the long-term efficacy, tolerance and compliance of ORM Narval Mandibular Repositioning Device (MRD) as a second-line treatment for patients with severe Obstructive Sleep Apnea Hypopnea (OSAH) syndrome who refuse or are intolerant to Continuous Positive Airway Pressure (CPAP) treatment.

Conditions

  • Obstructive Sleep Apnea Syndrome

Interventions

DEVICE

ORM Narval MRD

Sponsors & Collaborators

  • ResMed

    lead INDUSTRY

Principal Investigators

  • Marie-Françoise VECCHIERINI-BLINEAU, Dr · Hôtel Dieu, Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2019-02-28
Completion
2019-02-27

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01326143 on ClinicalTrials.gov